

The Nomination Committee in Moberg Pharma AB's (publ) (corporate org. no. 556697-7426) (the "Company") proposal for decisions of the Annual General Meeting the 30th October, 2019 at 4:00 p.m.

Note that special circumstances exist whereby all proposals refer to the prolonged fiscal year July 1, 2019 - December 31, 2020. The next Annual General Meeting will take place during the second quarter of 2021.

Proposal for Chairman of the Annual General Meeting

The Nomination Committee consists of the Chairman Gillis Cullin representing Östersjöstiftelsen and the members Fredrik Persson representing Zimbrine Holding, Erik Lindbärg and Peter Wolpert, Chairman of the Board of Directors in the Company.

Chairman of the Annual General Meeting

The Nomination Committee proposes that Peter Wolpert is elected as Chairman of the Annual General Meeting of shareholders.

Election of the Board of Directors and the Chairman of the Board of Directors as well as proposal of fees to the Board members and the Auditor

The Nomination Committee proposes that the Board of Directors shall consist of four persons and no deputies.

The Nomination Committee proposes no changes to the Board of Directors with re-election of Peter Wolpert as executive Chairman of the Board of Directors and re-election of Mattias Klintemar, Andrew B. Hochman and Fredrik Granström as Board members of the Board of Directors for a period until the next Annual General Meeting.

The Nomination Committee proposes that an aggregate annual fee of SEK 870,000 shall be paid to the Board members, of which SEK 360,000 to the Chairman of the Board of Directors and SEK 170,000 for all other Board members elected by the Annual General Meeting. In order to compensate for the additional work that Peter will perform in the Company in the capacity of executive Chairman of the Board, the Nomination Committee also proposes a fee of SEK 61,000 per month to Peter Wolpert.

The Nomination Committee proposes, in accordance with the Board of Directors' recommendation, re-election of EY as Company Auditors, with Andreas Troberg as responsible Auditor for a period until the end of the next Annual General Meeting.

The Nomination Committee proposes that fees to the Auditors, for a period until the end of the Annual General Meeting, are to be paid as per approved invoice.

Stockholm, September 2019

The Nomination Committee in Moberg Pharma AB (publ)